Research Journal of Pharmacy and Technology

Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Effect of Calcium and Vitamin D Supplements as an Adjuvant Therapy to Metformin on Lipid Profile in Vitamin D Deficient/Insufficient Polycystic Ovary Syndrome Patients:A Randomized, Placebo-Controlled Clinical Trial


Affiliations
1 Department of Pharmaceutics and Pharmaceutical Technology, Damascus University, Damascus, Syrian Arab Republic
2 Department of Embryology and Reproductive Medicine, Damascus University, Damascus, Syrian Arab Republic
     

   Subscribe/Renew Journal


Objective: This study aims to investigate the impact of combining calcium and vitamin D supplements with metformin on lipid profile in vitamin D deficient/insufficient polycystic ovary syndrome (PCOS) women. Study design: A randomized, placebo-controlled clinical trial. Setting: Damascus University of Obstetrics and Gynecology Hospital and Orient Hospital, in Damascus, Syria. Materials and methods: Forty PCOS women with 25-hydroxyvitamin D < 30 ng/mL were randomly assigned to take either metformin (1500 mg/daily) plus placebo or metformin (1500 mg/daily) plus calcium (1000 mg/daily) and vitamin D3 (6000 IU/daily) orally for 8 weeks. Fasting serum levels of total cholesterol (TC), high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL), triglyceride (TG) and non-HDL cholesterol (non-HDL) were detected at the baseline and after 8 weeks of intervention. Results: Of all participants, thirty-four completed the study. After 8 weeks of intervention, calcium and vitamin D levels increased significantly in the supplementation group, but no significant changes in the lipid profile were noticed in both groups. Conclusions: Adding calcium and vitamin D to metformin therapy had no superior effect on improving lipid profile in vitamin D deficient/insufficient subjects with PCOS. The Clinical Trial Registration Number is NCT03792984.

Keywords

Polycystic Ovary Syndrome, Lipid Profile, Calcium, Vitamin D, Metformin.
Subscription Login to verify subscription
User
Notifications
Font Size


  • Goodarzi MO et al. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nature Reviews Endocrinology. 2011;7(4):219–31.

  • Azziz R et al. Polycystic ovary syndrome. Nature Reviews Disease Primers. 2016;2:16057.

  • Krul-Poel YHM et al. The role of vitamin D in metabolic disturbances in polycystic ovary syndrome: a systematic review. European Journal of Endocrinology. 2013;169(6):853–65.

  • Raja-khan N et al. The physiological basis of complementary and alternative medicines for polycystic ovary syndrome. American Journal of Physiology Endocrinology and Metabolism. 2011;301(1):E1–10.

  • Foroozanfard F et al. Effects of zinc supplementation on markers of insulin resistance and lipid profiles in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Experimental and Clinical Endocrinology & Diabetes. 2015;123(4):215–20.

  • Mohammadi E et al. Effects of omega-3 fatty acids supplementation on serum adiponectin levels and some metabolic risk factors in women with polycystic ovary syndrome. Asia Pacific journal of clinical nutrition. 2012;21(4):511–8.

  • Asemi Z et al. Metabolic response to folate supplementation in overweight women with polycystic ovary syndrome: A randomized double-blind placebo-controlled clinical trial. Molecular Nutrition & Food Research. 2014;58(7):1465–73.

  • Wang H et al. Vitamin D and Chronic Diseases. Aging and disease. 2017;8(3):346–53.

  • Irani M, Merhi Z. Role of vitamin D in ovarian physiology and its implication in reproduction: a systematic review. Fertility and Sterility. 2014;102(2):460–468.e3.

  • Wehr E et al. Association of hypovitaminosis D with metabolic disturbances in polycystic ovary syndrome. European Journal of Endocrinology. 2009;161(4):575–82.

  • Li HWR et al. Vitamin D deficiency is common and associated with metabolic risk factors in patients with polycystic ovary syndrome. Metabolism: Clinical and Experimental. 2011;60(10):1475–81.

  • Hahn S et al. Low serum 25-hydroxyvitamin D concentrations are associated with insulin resistance and obesity in women with polycystic ovary syndrome. Experimental and Clinical Endocrinology & Diabetes. 2006;114(10):577–83.

  • Mishra S et al. Hypovitaminosis D and associated cardiometabolic risk in women with PCOS. Journal of Clinical and Diagnostic Research. 2016;10(5):BC01-BC04.

  • Patra SK et al. Vitamin D as a predictor of insulin resistance in Polycystic Ovarian Syndrome. Diabetes & Metabolic Syndrome. 2012;6(3):146–9.

  • Pal L et al. Vitamin D status relates to reproductive outcome in women with polycystic ovary syndrome: secondary analysis of a multicenter randomized controlled trial. The Journal of Clinical Endocrinology & Metabolism. 2016;101(8):3027–35.

  • Ott J et al. Parameters for calcium metabolism in women with polycystic ovary syndrome who undergo clomiphene citrate stimulation: a prospective cohort study. European Journal of Endocrinology. 2012;166(5):897–902.

  • Chaudhuri JR et al. Deficiency of 25-Hydroxyvitamin D and Dyslipidemia in Indian Subjects. Journal of Lipids. 2013;2013:623420.

  • Vinarova L et al. The mechanism of lowering cholesterol absorption by calcium studied by using an in vitro digestion model. Food and Function. 2016;7(1):151–63.

  • Reid IR. Effects of calcium supplementation on circulating lipids: potential pharmacoeconomic implications. Drugs and Aging. 2004;21(1):7–17.

  • Wehr E et al. Effect of vitamin D3 treatment on glucose metabolism and menstrual frequency in polycystic ovary syndrome women: a pilot study. Journal of Endocrinological Investigation. 2011;34(10):757–63.

  • Raja-Khan N et al. High-dose vitamin D supplementation and measures of insulin sensitivity in polycystic ovary syndrome: a randomized, controlled pilot trial. Fertility and Sterility. 2014;101(6):1740–6.

  • Irani M et al. Vitamin D supplementation decreases TGF-β1 bioavailability in PCOS: A randomized placebo-controlled trial. The Journal of Clinical Endocrinology & Metabolism. 2015;100(11):4307–14.

  • Asemi Z et al. Calcium plus vitamin D supplementation affects glucose metabolism and lipid concentrations in overweight and obese vitamin D deficient women with polycystic ovary syndrome. Clinical Nutrition. 2015;34(4):586–92.

  • The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertility and Sterility. 2004;81(1):19–25.

  • Holick MF et al. Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine society clinical practice guideline. The Journal of Clinical Endocrinology and Metabolism. 2011;96(7):1911–30.

  • Yildiz BO et al. Visually scoring hirsutism. Human Reproduction Update. 2010;16(1):51–64.

  • Wehmeier K et al. Inhibition of apolipoprotein AI gene expression by 1, 25-dihydroxyvitamin D3. Biochimica et Biophysica Acta. 2005;1737(1):16–26.

  • Wang JH et al. Serum cholesterol and expression of ApoAI, LXRβ and SREBP2 in vitamin D receptor knock-out mice. Journal of Steroid Biochemistry and Molecular Biology. 2009;113(3–5):222–6.

  • Abdel-Rehim WM et al. The possible antidiabetic effects of vitamin D receptors agonist in rat model of type 2 diabetes. Molecular and Cellular Biochemistry. 2018.

  • Abdel-Rehim WM et al. The possible antidiabetic effects of vitamin D receptors agonist in rat model of type 2 diabetes. Molecular and Cellular Biochemistry. 2018;450(1-2):105-112.


Abstract Views: 244

PDF Views: 0




  • Effect of Calcium and Vitamin D Supplements as an Adjuvant Therapy to Metformin on Lipid Profile in Vitamin D Deficient/Insufficient Polycystic Ovary Syndrome Patients:A Randomized, Placebo-Controlled Clinical Trial

Abstract Views: 244  |  PDF Views: 0

Authors

Sally Kadoura
Department of Pharmaceutics and Pharmaceutical Technology, Damascus University, Damascus, Syrian Arab Republic
Marwan Alhalabi
Department of Embryology and Reproductive Medicine, Damascus University, Damascus, Syrian Arab Republic
Abdul Hakim Nattouf
Department of Pharmaceutics and Pharmaceutical Technology, Damascus University, Damascus, Syrian Arab Republic

Abstract


Objective: This study aims to investigate the impact of combining calcium and vitamin D supplements with metformin on lipid profile in vitamin D deficient/insufficient polycystic ovary syndrome (PCOS) women. Study design: A randomized, placebo-controlled clinical trial. Setting: Damascus University of Obstetrics and Gynecology Hospital and Orient Hospital, in Damascus, Syria. Materials and methods: Forty PCOS women with 25-hydroxyvitamin D < 30 ng/mL were randomly assigned to take either metformin (1500 mg/daily) plus placebo or metformin (1500 mg/daily) plus calcium (1000 mg/daily) and vitamin D3 (6000 IU/daily) orally for 8 weeks. Fasting serum levels of total cholesterol (TC), high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL), triglyceride (TG) and non-HDL cholesterol (non-HDL) were detected at the baseline and after 8 weeks of intervention. Results: Of all participants, thirty-four completed the study. After 8 weeks of intervention, calcium and vitamin D levels increased significantly in the supplementation group, but no significant changes in the lipid profile were noticed in both groups. Conclusions: Adding calcium and vitamin D to metformin therapy had no superior effect on improving lipid profile in vitamin D deficient/insufficient subjects with PCOS. The Clinical Trial Registration Number is NCT03792984.

Keywords


Polycystic Ovary Syndrome, Lipid Profile, Calcium, Vitamin D, Metformin.

References